Mirati Therapeutics, Inc. (MRTX) on Wednesday announced that it has received conditional marketing authorization from the European Commission (EC) for KRAZATI (adagrasib) as a targeted treatment option for advanced non-small cell lung cancer patients with KRASG12C mutation and disease progression after at least one prior systemic therapy.
This authorization is valid in all 27 EU member states, Iceland, Norway, and Liechtenstein.
The approval follows the positive opinion of the Committee for Medicinal Products for Human Use (CHMP) in November 2023.
Additionally, Adagrasib is being studied for advanced KRASG12C-mutated solid tumors, including NSCLC, colorectal cancer, and pancreatic cancer.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.